Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring product that are intended to enable people with diabetes to confidently live their lives with ease. Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring (''CGM'') system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.

Research Grants 1 show all


$879.5K
2000

Publications 14 show all

  • 7
    Blood Glucose Self-Monitoring/instrumentation
  • 6
    Blood Glucose/analysis
  • 5
    Diabetes Mellitus, Type 1/blood
  • 3
    Diabetes Mellitus, Type 2/blood
  • 2
    Insulin Infusion Systems
  • 1
    Algorithms
  • 1
    Biosensing Techniques/methods
  • 1
    Blood Glucose Self-Monitoring/methods
  • 1
    Blood Glucose Self-Monitoring/psychology
  • 1
    Boronic Acids/chemistry

Patents 365show all

  • 160
    A61B - Diagnosis
  • 90
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 18
    H05K - Printed circuits
  • 15
    G16H - Healthcare informatics, i.e. information and communication technology [ict] specially adapted for the handling or processing of medical or healthcare data
  • 11
    A61N - Electrotherapy
  • 11
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 10
    A61M - Devices for introducing media into, or onto, the body
  • 9
    G06F - Electric digital data processing
  • 7
    G01J - Measurement of intensity, velocity, spectral content, polarisation, phase or pulse characteristics of infra-red, visible or ultra-violet light
  • 6
    C07D - Heterocyclic compounds

Clinical Trials 8show all

8N/A

SEC Filings show all


6
D

Contact Information

20451 SENECA MEADOWS PARKWAY
Germantown, MD 20876
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$325,799,98951-1002018-06-29Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2018-06-29$149,500,000Post Ipo Equity
2015-08-11$9,999,998Series E
2010-05-01$10,000,000Series Unknown
2016-07-13$30,000,000Post Ipo DebtSilicon Valley Bank, Oxford Finance LLC
2002-05-10$15,000,000Series Unknown
2011-11-10$30,000,000Series Unknown
2009-05-15$10,000,000Series Unknown
2014-06-05$20,000,000Series UnknownNew Enterprise Associates (NEA), Abingworth, Greenspring Associates, Delphi Ventures, Anthem Capital Management, HealthCare Ventures
2014-08-19$299,991Series D
2017-05-31$41,000,000Post Ipo EquityNew Enterprise Associates (NEA), Roche Finance
2014-04-19$10,000,000Debt FinancingOxford Finance LLC

SEC Form D Funding Events

DateOfferedSoldType
2014-08-14$299,991$299,991Option to Acquire, Security to be Acquired, Other
2014-06-02$23,600,000$9,935,928Equity
2011-11-14$54,082,773$30,582,783Equity, Security to be Acquired, Other
2010-05-13$30,000,000$10,000,000Equity, Option to Acquire, Security to be Acquired, Other
2002-04-19Unknown Unknown Other (Paper Filing)

Key Executives

  • Marc R. Schneebaum
    Executive Officer, Director
  • M. James Barrett, Ph.D.
    Executive Officer, Director, Promoter
  • James H. Cavanaugh, Ph.D.
    Director
  • Bradley G. Lorimier
    Director
  • Charles W. Newhall III
    Director
  • Gerard Vaillant
    Director
  • Francis H. Zenie
    Director
  • M. James Barrett
    Director
  • Stephen P. DeFalco
    Director
  • Timothy T. Goodnow
    Director, Executive Officer
  • John W. Littlechild
    Director
  • Douglas A. Roeder
    Director
  • Ed Fiorentino
    Director
  • Peter Justin Klein
    Director
  • Ed Fiorentno
    Director